1-(methylamino)tridecane | 45165-81-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(methylamino)tridecane
• 英文别名: n-tridecyl-n-methylamine；1-dodecyldimethyl amine；Methyltridecylamine；N-methyltridecan-1-amine
• CAS: 45165-81-9
• 化学式: C₁₄H₃₁N
• 分子量: 213.407
• InChiKey: XMRPIOZXPHTSCE-UHFFFAOYSA-N

物化性质

• 沸点：
  266.5±3.0 °C(Predicted)
• 密度：
  0.794±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  15
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为产物：
  描述：

  1-十二烯十二碳烯α-十二碳烯α-十二碳烯 、 四甲基甲烷二胺 在 硫酸 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 生成 N,N-二甲基十三烷胺 、 1-(methylamino)tridecane
  参考文献：
  名称：

  Competing hydride transfer and ene reactions in the aminoalkylation of 1-alkenes with N,N-dimethylmethyleniminium ions. A literature correction

  摘要：

  DOI：

  10.1021/jo00172a018

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• Transesterification Reacton of Triglycerides and Monohydric Alcohols
  申请人：Halpern Marc E.

  公开号：US20090069585A1

  公开（公告）日：2009-03-12

  A process for producing monoesters and glycerol from triglycerides and monohydric alcohols by transesterification in the presence of phase-transfer catalysts and base initiators, produced in a batch or continuous mode. Reaction mixtures comprising triglycerides such as vegetable triglycerides, monohydric alcohols such as methanol or ethanol, base initiators such as alkali metal hydroxides or carbonates and phase-transfer catalysts such as quaternary ammonium or quaternary phosphonium salts for performing transesterification reactions. The reaction product comprises a mixture of monoesters and glycerol. The monoesters produced are useful as fuels, cleaning solvents and other industrial applications. For example, fatty acid methyl esters are produced by the transesterification reaction between fatty vegetable triglycerides and methanol in the presence of catalytic quantities of both methyl tricaprylyl ammonium chloride and sodium hydroxide at a temperature of about 70° C.

  一种通过在存在相转移催化剂和碱引发剂的情况下，通过酯交换从甘油三酯和一元醇中生产单酯和甘油的方法，可以批量或连续生产。反应混合物包括甘油三酯（如植物甘油三酯）、一元醇（如甲醇或乙醇）、碱引发剂（如碱金属氢氧化物或碳酸盐）和相转移催化剂（如季铵盐或季磷盐），用于进行酯交换反应。反应产物包括单酯和甘油的混合物。生产的单酯可用作燃料、清洁溶剂和其他工业应用。例如，通过在约70°C温度下，在催化量的甲基三辛基氯化铵和氢氧化钠的存在下，使脂肪植物甘油三酯和甲醇之间进行酯交换反应，可生产脂肪酸甲酯。
• Process for producing allyl halide compound
  申请人：——

  公开号：US20020107422A1

  公开（公告）日：2002-08-08

  There are disclosed a composition comprising (E)-1,4-dibromo-2-methyl-2-butene and (Z)-1,4-dibromo-2-methyl-2-butene, wherein the ratio of the E isomer to the total amount of the E and Z isomers is 0.9 or more; a process for producing the same and a process using the same to produce an allyl halide compound of formula (1): 1 wherein X denotes a bromine atom, Y denotes an ArS(O) 2 group or an RCOO group, wherein Ar denotes an aryl group which may be substituted and R denotes a hydrogen atom, a lower alkyl group or an aryl group which may be substituted, and the wavy line means that the derivative is a mixture of an E or Z geometrical isomer.

  本发明涉及一种包含(E)-1,4-二溴-2-甲基-2-丁烯和(Z)-1,4-二溴-2-甲基-2-丁烯的组合物，其中E异构体与E和Z异构体的总量之比为0.9或更高；一种生产该组合物的方法以及使用该组合物生产化合物的方法，所述化合物的分子式为（1）：其中X代表溴原子，Y代表ArS(O)2基团或RCOO基团，其中Ar代表可能被取代的芳基，R代表氢原子、低碳烷基或可能被取代的芳基，波浪线表示衍生物是E或Z几何异构体的混合物。
• METHOD OF MODULATING STABILITY OF SULFONATED DYE
  申请人：Indusegaram Sutharsiny

  公开号：US20090199352A1

  公开（公告）日：2009-08-13

  A method of modulating a stability of a sulfonated dye, particularly its ozonefastness. The method comprises providing a salt of the dye, wherein the salt comprises at least one organic cation selected from the group consisting of: a first organic cation having a positive charge delocalized between a nitrogen atom and at least one other heteroatom; a second organic cation having a positive charge delocalized between a nitrogen atom and at least two other atoms; and a third organic cation of formula (A): wherein: R p , R q and R r are each independently selected from a C 1-6 alkyl group; s is 0, 1, 2 or 3; and Ar is a C 6-12 aryl group or C 3-12 heteroaryl group.

  一种调节磺化染料稳定性的方法，特别是其臭氧稳定性。该方法包括提供染料的盐，其中该盐包括至少一种有机阳离子，所述有机阳离子选自以下组合中的至少一种：第一种有机阳离子，其正电荷分散在氮原子和至少另一种杂原子之间；第二种有机阳离子，其正电荷分散在氮原子和至少两种其他原子之间；以及具有以下公式（A）的第三种有机阳离子：其中：Rp、Rq 和 Rr 分别独立选择自 C1-6 烷基基团；s 为 0、1、2 或 3；Ar 为 C6-12 芳基基团或 C3-12 杂芳基团。
• [EN] 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY<br/>[FR] DÉRIVÉS DE 4-PHÉNYLAMINO-PYRIMIDINE AYANT UNE ACTIVITÉ D'INHIBITION D'UNE PROTÉINE KINASE
  申请人：VICHEM CHEMIE KUTATO KFT

  公开号：WO2011077171A1

  公开（公告）日：2011-06-30

  The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula -NH-SO2-R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

  该发明涉及一般式（I）的化合物及其药用可接受的盐和溶剂化合物，其中R1为卤素、乙烯基芳基、取代芳基、杂芳基或苯并[1,3]二噁唑基团，W为式-NH-SO2-R2或杂芳基或NHR3基团，其中R3为氢或杂芳基；n为1、2、3或4。此外，本发明涉及一种含有至少一种一般式（I）的化合物和/或其药用可接受的盐或溶剂化合物的药物组合物，并用于制备用于预防和/或治疗蛋白激酶相关疾病，特别是CDK9相关疾病，如细胞增殖性疾病、传染病、疼痛、心血管疾病和炎症的药物组合物。